Psoriasis
43 drugs122,230 FAERS reportsMedDRA PT
GET
/api/v1/reaction/psoriasisReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D011565
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
Source: U.S. National Library of Medicine — MeSH (Psoriasis)
Drugs reporting Psoriasis (43)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Sunflower Oil1100%
- 2Coal Tar41554%
- 3Brodalumab48325%
- 4Acitretin1,16924%
- 5Calcipotriene1,34820%
- 6Halobetasol22715%
- 7Secukinumab22,70914%
- 8Zinc Pyrithione114%
- 9Apremilast20,36614%
- 10Bimekizumab2,01913%
- 11Halcinonide199.9%
- 12Risankizumab7,5789.9%
- 13Fluocinonide5509.9%
- 14Ixekizumab3,2058.8%
- 15Diflorasone168.6%
- 16Iodoquinol37.9%
- 17Amcinonide67.1%
- 18Tazarotene886.6%
- 19Ustekinumab6,5226.5%
- 20Guselkumab2,1406.5%
- 21Acebutolol806.4%
- 22Clobetasol6826.2%
- 23Deucravacitinib1646.1%
- 24Desonide2805.8%
- 25Meperidine5025.5%
- 26Oxyquinoline25.3%
- 27Tildrakizumab905.2%
- 28Flurandrenolide165.1%
- 29Nitrogen54.8%
- 30Spesolimab164.7%
- 31Valerate2974.6%
- 32Alitretinoin54.3%
- 33Etanercept25,0324.2%
- 34Tapinarof684.0%
- 35Octinoxate143.9%
- 36Ketoconazole6493.8%
- 37Pyrithione213.7%
- 38Adalimumab25,1523.5%
- 39Levomenthol33.3%
- 40Fluocinolone1293.1%
- 41Ciclopirox772.7%
- 42Pimecrolimus432.7%
- 43Permethrin382.2%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Psoriatic Arthropathy11 shared · 0.22
- Skin Exfoliation13 shared · 0.16
- Dermatitis Atopic7 shared · 0.11
- Dry Skin11 shared · 0.11
- Erythema20 shared · 0.09
- Nasopharyngitis10 shared · 0.07
- Therapeutic Product Effect Incomplete7 shared · 0.07
- Inappropriate Schedule Of Product Administration11 shared · 0.07
- Eczema4 shared · 0.07
- Skin Burning Sensation4 shared · 0.06
Literature
Recent PubMed references pinned to Psoriasis as a MeSH major topic. About the reaction term itself — not about any specific drug.
- PRELP negatively regulates IL-17A-mediated proliferation and the inflammatory response in psoriasis.Signal transduction and targeted therapy · 2026 · He CC, Lei MX, Jiang JW, et al.PMID 42204138DOI 10.1038/s41392-026-02693-6
- Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.Skin therapy letter · 2026 · Adam SR, Sauder MPMID 42202148
- Deciphering the Underlying Mechanisms Linking Psoriasis and IgA Nephropathy.Journal of immunology research · 2026 · Tang Z, Wu J, Dong M, et al.PMID 42200798DOI 10.1155/jimr/1862174
- Multi-omics insights into spondyloarthritis and psoriatic arthritis: integrating genomics, transcriptomics, proteomics, and the microbiome for immunological and clinical translation.Frontiers in immunology · 2026 · Zhu M, Li R, Wu S, et al.PMID 42199404DOI 10.3389/fimmu.2026.1831823
- The Gut-Skin and Gut-Thyroid Axis in Autoimmunity: Roles of Dysbiosis, Microbial Metabolites, Immune Dysregulation, and Diet in Psoriasis and Hashimoto's Thyroiditis.Nutrients · 2026 · Ribačuka S, Upmale-Engela S, Vaivode I, et al.PMID 42196960DOI 10.3390/nu18101501
- IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.International journal of molecular sciences · 2026 · Andrzejczak K, Kucharczyk E, Sternak A, et al.PMID 42196416DOI 10.3390/ijms27104441
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.